Figure 1.

Figure 1.

Change in FVC from Baseline of Bexotegrast 320 mg Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis – Modified Intent to Treat Population

Format

PNG

Source

Pliant Therapeutics, Inc.

Downloads